CurrentUnitedHealthcarePolicy N/A

Palynziq (pegvaliase-pqpz) prior authorization criteria

Defines UnitedHealthcare prior authorization and reauthorization criteria for the specialty drug Palynziq for treatment of adult patients with phenylketonuria (PKU). Applies to pharmacy benefit management and prescribing providers seeking coverage for pegvaliase.

Policy Summary

PayerUnitedHealthcare

PolicyPalynziq (pegvaliase-pqpz) prior authorization criteria

Policy CodePolicy N/A

Change TypeClarification / Addition

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis of PKU, current blood phenylalanine concentration, active phenylalanine-restricted diet, and absence of concurrent sapropterin or Sephience therapy for approval.

SourceLink

POLICY UPDATE CHANGES

Simplified reauthorization criteria to standard documentation of positive clinical response language (6/2025).

Sephience (sepiapterin) added to the list of agents that must not be used in combination with Palynziq (11/2025).

12Authorization period for initial and reauthorization

>600Blood Phe threshold for initial therapy

20%Relative reduction in blood Phe for reauthorization example

Medical Necessity Criteria for Palynziq (pegvaliase-pqpz)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Authorization (Medical Necessity)

Palynziq will be approved based on all of the following criteria:

ALL of the following

Diagnosis of phenylketonuria (PKU)
Patient has a blood phenylalanine concentration greater than 600 micromol/L> 600 micromol/L
Patient is actively on a phenylalanine-restricted diet
Patient is not receiving Palynziq in combination with sapropterin dihydrochloride or Sephience (sepiapterin)

Reauthorization (Continuation)

Palynziq will be approved for reauthorization when ALL of the following are met:

ALL of the following

Documentation of positive clinical response
Examples: blood phenylalanine concentration less than 600 micromol/L, or 20% reduction in blood phenylalanine concentration from pretreatment baseline
Patient is actively on a phenylalanine-restricted diet
Patient is not receiving Palynziq in combination with sapropterin dihydrochloride or Sephience (sepiapterin)

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior authorization required

Providers must obtain prior authorization before initiating Palynziq. The request must document a diagnosis of phenylketonuria (PKU), a current blood phenylalanine concentration greater than 600 micromol/L for initiation, that the patient is actively on a phenylalanine‑restricted diet, and that the patient is not receiving Palynziq in combination with sapropterin dihydrochloride or Sephience (sepiapterin). If approved, authorization will be issued for 12 months.

Documentation Required

Documentation for reauthorization

For reauthorization, submit documentation demonstrating a positive clinical response such as laboratory results showing blood phenylalanine concentration less than 600 micromol/L or a ≥20% reduction from pretreatment baseline. Also document that the patient remains on a phenylalanine‑restricted diet and is not receiving concomitant sapropterin dihydrochloride or Sephience (sepiapterin).

Denial Risk

Combination therapy exclusion

Coverage may be denied if Palynziq is prescribed in combination with sapropterin dihydrochloride or Sephience (sepiapterin); combination use with these agents is excluded from approval.

Note

State mandates and benefit plan limits

State mandates, any applicable federal requirements, and the member's specific benefit plan may affect coverage decisions. Additional utilization management programs, medical necessity rules, or supply limits may also apply.

Clinical and Administrative Background

Palynziq (pegvaliase-pqpz) is a phenylalanine‑metabolizing enzyme therapy indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations >600 micromol/L on existing management. The policy requires that patients remain actively on a phenylalanine‑restricted diet while receiving therapy and specifies that Palynziq must not be prescribed in combination with sapropterin dihydrochloride or Sephience (sepiapterin).

For ongoing therapy, the policy documents expected response thresholds used for reauthorization. Reauthorization requires documentation of a positive clinical response, for example achieving blood phenylalanine concentration <600 micromol/L or a ≥20% reduction in blood phenylalanine from pretreatment baseline. Approvals (initial and reauthorization) are issued for 12 months. State mandates, federal requirements, and the member’s benefit plan may also affect coverage and utilization management.

Policy Changes

2025-11administrative - added agent to exclusion listLatest

Sephience (sepiapterin) was added to the list of agents that must not be used in combination with Palynziq; references and document control updated.

2025-06administrative - clarified (not material)

Simplified reauthorization criteria to standard documentation of positive clinical response language (examples: Phe <600 micromol/L or 20% reduction from baseline).